P2116
吡非尼酮
≥97% (HPLC), powder, antifibrotic agent
别名:
5-甲基-1-苯基-2-(1H)-吡啶酮
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H11NO
化学文摘社编号:
分子量:
185.22
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
一般描述
吡非尼酮（5-甲基-1-苯基-2-[1H]-吡啶酮）是合成的吡啶 衍生物。
应用
吡非尼酮用于：
- 作为兔的术后滴眼剂，分析其抗纤维化作用，改进青光眼滤过手术
- 作为抗瘢痕形成剂，检查其是否影响兔植入青光眼引流装置（GDD）后的异物反应
- 在人眼眶成纤维细胞（hOF）原代培养物中测试其抗纤维化潜力
- 作为肿瘤坏死因子（TNFα）抑制剂，研究其在缺氧中的作用
生化/生理作用
吡非尼酮可抑制胶原生成和成纤维细胞增殖。在多种肺纤维化动物模型和临床试验中显示出抗纤维化和抗炎属性。
吡非尼酮用于治疗特发性肺纤维化（IPF）。有助于减少肺功能下降引起的衰弱，延长无进展生存期。吡非尼酮可抑制人Tenon′s 囊成纤维细胞胶原蛋白的增殖和收缩。
抑制胶原生成和成纤维细胞增殖。
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
Arata Azuma
Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the
CX3CL1 (fractalkine) and TNF alpha production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling
Szukiewicz D, et al.
Inflammation Research, 63(3), 179-189 (2014)
Huzaifa I Adamali et al.
Drug design, development and therapy, 6, 261-272 (2012-10-12)
Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster L H, et al.
European Respiratory Review, 26(146), 170057-170057 (2017)
Talmadge E King et al.
The New England journal of medicine, 370(22), 2083-2092 (2014-05-20)
In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持